Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome

被引:43
|
作者
Kaushik, Shalini V. [1 ,2 ]
Plaisance, Eric P. [2 ,3 ]
Kim, Teayoun [1 ,2 ]
Huang, Edmond Y. [1 ,2 ]
Mahurin, A. Jack [5 ]
Grandjean, Peter W. [2 ,4 ]
Mathews, Suresh T. [1 ,2 ]
机构
[1] Auburn Univ, Dept Nutr & Food Sci, Auburn, AL 36849 USA
[2] Auburn Univ, Boshell Diabet & Metab Dis Res Program, Auburn, AL 36849 USA
[3] Auburn Univ, Dept Anat Physiol & Pharmacol, Auburn, AL 36849 USA
[4] Auburn Univ, Dept Kinesiol, Auburn, AL 36849 USA
[5] Baptist Family Med Residency Program, Montgomery, AL 36116 USA
关键词
fetuin-A; niacin; Niaspan; alpha 2-HS glycoprotein; metabolic syndrome; triglycerides; MOLECULAR-WEIGHT ADIPONECTIN; RECEPTOR TYROSINE KINASE; INSULIN-RESISTANCE; NICOTINIC-ACID; INFLAMMATORY MARKERS; MEDIA THICKNESS; PLASMA; ASSOCIATION; INHIBITOR; GENE;
D O I
10.1002/dmrr.967
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Fetuin-A, a liver-secreted phosphoprotein and physiological inhibitor of insulin receptor tyrosine kinase, is associated with insulin resistance, metabolic syndrome (MetS), and an increased risk for type 2 diabetes. However, studies on the modulation of circulating levels of fetuin-A are limited. The goal of this study was to determine the effect of niacin administration on serum total- and phosphorylated fetuin-A (phosphofetuin-A) concentrations in individuals with MetS and correlate with changes in serum lipids, insulin sensitivity, and markers of inflammation. Methods Fifteen sedentary, obese, male participants, who met the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for MetS, were treated with extended-release niacin (Niaspan) for 6 weeks. Blood samples were obtained before and after treatment with niacin. Results Serum fetuin-A and phosphofetuin-A concentrations were decreased following niacin administration (p < 0.005). Changes in fetuin-A concentrations were correlated with changes in triglyceride (r = 0.62, p = 0.01) and C-reactive protein (CRP) concentrations (r = 0.58, p, < 0.05) after nacin treatment. Changes in high-density lipoproteins (HDL)-cholesterol following niacin intervention were negatively correlated with changes in serum fetuin-A (p < 0.05) and phosphofetuin-A concentrations (p < 0.05). Serum cortisol levels were significantly elevated after niacin administration. Conclusions Niacin treatment lowers serum total- and phosphofetuin-A concentrations in individuals with MetS, and these changes correlate with the beneficial changes in serum lipids. Because niacin is known to induce insulin resistance, these findings suggest that fetuin-A may not be a mediator of niacin-induced insulin resistance but it may blunt the insulin resistance induced by niacin by decreasing its circulating concentrations. Copyright (c) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:427 / 434
页数:8
相关论文
共 50 条
  • [1] Association of fetuin-A with decreased serum triglyceride after six weeks of extended-release niacin intervention in individuals with metabolic syndrome
    Mathews, S. T.
    Kaushik, S. V.
    Plaisance, E. P.
    Kim, T.
    Huang, E.
    Mahurin, A. J.
    Grandjean, P. W.
    DIABETOLOGIA, 2008, 51 : S374 - S374
  • [2] Once-Daily Extended-Release Niacin Lowers Serum Phosphorus Concentrations in Patients With Metabolic Syndrome Dyslipidemia
    Hu, Susie
    Shearer, Gregory C.
    Steffes, Michael W.
    Harris, William S.
    Bostom, Andrew G.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (01) : 181 - 182
  • [3] EXTENDED-RELEASE NIACIN/LAROPIPRANT LOWERS SERUM PHOSPHORUS CONCENTRATIONS IN DYSLIPIDEMIC PATIENTS
    Bostom, Andrew G.
    Maccubbin, Darbie
    Tipping, Diane
    Kuznetsova, Olga
    Hanlon, William A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [4] Population-based response estimates for extended-release niacin and extended-release niacin/lovastatin versus other dyslipidemia therapy in patients with the metabolic syndrome
    Stanek, EJ
    Quimbo, R
    Cziraky, MJ
    Charland, SL
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (05) : E84 - E84
  • [5] Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome
    Bays, Harold E.
    Shah, Arvind
    Lin, Jianxin
    Sisk, Christine McCrary
    Paolini, John F.
    Maccubbin, Darbie
    JOURNAL OF CLINICAL LIPIDOLOGY, 2010, 4 (06) : 515 - 521
  • [6] Modeled effects of extended-release niacin versus micronized fenofibrate in a metabolic syndrome population
    Stanek, Eric J.
    Quimbo, Ralph
    Cziraky, Mark J.
    Charland, Scott L.
    DIABETES, 2006, 55 : A519 - A519
  • [7] Niacin Extended-Release/Simvastatin
    Mark Sanford
    Monique P. Curran
    Drugs, 2008, 68 : 2373 - 2386
  • [8] Niacin Extended-Release/Simvastatin
    Sanford, Mark
    Curran, Monique P.
    DRUGS, 2008, 68 (16) : 2373 - 2386
  • [9] Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy Subjects
    Lauring, Brett
    Dishy, Victor
    De Kam, Pieter-Jan
    Crumley, Tami
    Wenning, Larissa
    Liu, Fang
    Sisk, Christine
    Wagner, John
    Lai, Eseng
    AMERICAN JOURNAL OF THERAPEUTICS, 2015, 22 (05) : 367 - 376
  • [10] Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes
    Bostom, Andrew G.
    MacLean, Alexandra A.
    Maccubbin, Darbie
    Tipping, Diane
    Giezek, Hilde
    Hanlon, William A.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2011, 5 (04) : 281 - 287